DUBLIN, June 26, 2023 /PRNewswire/ -- The "Cancer Therapies: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
Global Cancer Therapies Market to Reach $335.9 Billion by 2030
In the changed post COVID-19 business landscape, the global market for Cancer Therapies estimated at US$171.6 Billion in the year 2022, is projected to reach a revised size of US$335.9 Billion by 2030, growing at a CAGR of 8.8% over the analysis period 2022-2030.
Chemotherapy, one of the segments analyzed in the report, is projected to record a 8.1% CAGR and reach US$97 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Targeted Therapy segment is readjusted to a revised 9% CAGR for the next 8-year period.
The U.S. Market is Estimated at $67.6 Billion, While China is Forecast to Grow at 10.3% CAGR
The Cancer Therapies market in the U.S. is estimated at US$67.6 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$27.9 Billion by the year 2030 trailing a CAGR of 10.3% over the analysis period 2022 to 2030.
Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.4% and 9% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 10.1% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$19.2 Billion by the year 2030.
What`s New for 2023?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Key Topics Covered:
MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Impact of Covid-19 and a Looming Global Recession
- Cancer Therapies: An Outlook
- Chemotherapy & Targeted Therapy Lead the Global Cancer Therapies Market
- By Cancer Type
- USA Leads the Cancer Therapies Market
- Biotherapies to Drive Growth
- Rise in Cancer Incidence & Access to Modern Therapeutics Foster Growth
- Total Number of New Cancer Cases by Type: 2018
- Total Number of Cancer Deaths by Type: 2018
- Cancer Incidence by Region: 2018
- Cancer Mortality by Region: 2018
- Age-Standardized Incidence and Mortality Rates of All Cancers (per 100000 Population) by Region: 2018
- Cancer Research Spending Continues to Witness Growth
- Number of FDA-Approved Cancer Drugs: 2010-2018
- Select Cancer Drug Approvals in 2019
- Select Cancer Drug Approvals in 2018
- Cancer Drug Pipeline to Change the Pharma Landscape
- Increasing Share of Cancer Drugs as % Of Total Pharma Drug Pipeline: 2010-2019
- Cancer Therapies - Global Key Competitors Percentage Market Share in 2022 (E)
- Select Leading Cancer Drugs Worldwide by Sales: 2018
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
MARKET TRENDS & DRIVERS
- Industry Focuses on New Approaches to Treat Cancer
- Recent Advancements in Cancer Drug Discovery
- A New Immunotherapy Technique that Improves Efficacy and Safety of Cancer Treatment Developed by an Institute for Molecular Engineering Research Team
- Lymphoma Therapy Developed by BeiGene Secures US FDA Approval
- New Linker Technology for Enhancing Stability of ADCs
- Personalized Medicine Gains Importance
- Companion Diagnostics Accelerate Role of Personalized Medicine in Cancer Care
- North American Companion Diagnostics Market (2019)
- European Companion Diagnostics Market by Disease Area (2019)
- Innovations in Cancer Drug Delivery: Key Factor in Product Differentiation
- Peptoid-based Nanotubes Allow Precise, Targeted Delivery of Cancer Drugs
- Combination Therapy: A Double Whammy Success
- Patent Expiries of Branded Drugs to Trigger Generic Competition
- Patent Expiries of Major Biopharmaceutical Drugs in the US and Europe
- Gene Therapy based Approaches Present Potential Weapon for Battle against Cancer
- Development of Novel Drug Candidates and Potential Therapies
- Non-Viral Gene Therapy to Expedite Cancer Research and Introduction of New Therapies
- Rise in Patient Assistance Programs (PAPs)
- Top Financial Concerns for Cancer Patients: Ranked In Order of Influence
- Oral Oncolytic Abandonment Rate (in %) by Patient Out-of-Pocket Expenses
- Growth Drivers and Restraints
- Demographics & Lifestyles Raise the Risk of Cancer
- Percentage Breakdown of New Cases for All Cancers by Gender (2019)
- Percentage Breakdown of New Cases for Colon and Rectum Cancers by Gender (2019)
- Percentage Breakdown of New Cases for Lung & Bronchus Cancers by Gender (2019)
- Unmet Needs Leave Scope for Further Research and Development
- Low Entry Barriers in Cancer Research Encourages Breakthrough Developments
- Increasing Investments by National Health Authorities
- NCI Funding for Cancer Research (2002, 2008, 2014 and 2020)
- Improved Screening, Diagnosis & Patient Survival Rates Trigger Growth
- Molecular Imaging of Cancer: Critical in Improving Patient Outcomes
- Innovations, Improvements, and Approvals Propel Growth
- Select Cancer Drug Approvals (2018 & 2019)
- Emerging Challenges in Cancer Drug Development
- Drug Failures Deter Prospects of New Therapies
- High Prices of Targeted Therapies Act as a Speed Breaker
- Estimated Average Monthly Cost of Select Leading Cancer Drugs in the US as of 2016
- Cancer Drug Approval Processes Need to Become More Flexible for Encouraging Innovation
- Limited Tumor Specificity and Toxicity
- Complicated Treatment Protocols: A Major Stumbling Block in Patient Compliance
- Reduced Smoking
- Global Cigarette Consumption Per Capita by Select Countries for 1970 and 2018
- Reimbursement Coverage Remains a Major Challenge
- Increase in Multidrug Resistance
- Stringent Regulations Delay Market Approval
- Challenges Encountered in Clinical Trials
- Overview of Cancer Therapy Segments
- Immunotherapy: A Promising Segment
- Global Cancer Immunotherapy Market by Therapy Type (in %) for 2019
- Monoclonal Antibodies for Cancer Treatment
- Monoclonal Antibodies in Late-Stage Clinical Trials for Cancer Treatment
- Vaccines: A Promising Future Area of Cancer Therapeutics
- Approved Therapeutic Cancer Vaccines Worldwide
- CAR-T Therapy: An Innovative Therapy Focused on Engineering of Patients' Immune Cells for Cancer Treatment
- UK Researchers New Approach Holds Potential to Boost Immunotherapies
- Targeted Therapy: An Overview
- Types of Targeted Therapy
- Chemotherapy: An Overview
- Types of Chemotherapy
- Risks Associated with Chemotherapy
- Hormone Therapy
- Drug Classes in Hormone Therapy
- CANCER TYPES, APPROVED AND PIPELINE DRUGS
- Prostate Cancer
- Global Sales of Leading Prostate Cancer Drugs in US$ Million: 2018
- Select General Risk Factors and their Relative Risk Rate in Prostate Cancer
- Select FDA Approved Drugs for Palliative Treatment of Advanced Prostate Cancer
- Select Drugs that Received Approval for Castration-Resistant Prostate Cancer (CRPC)
- Prostate Cancer Phase IV Completed Clinical Trials with Results
- Lung Cancer
- Age-Standardized Lung Cancer Rates for Select Countries
- Age-Standardized Lung Cancer Rates in Men for Select Countries
- Age-Standardized Lung Cancer Rates in Women for Select Countries
- Select FDA-Approved Non-Small Cell Lung Cancer Drugs
- Select Phase IV Completed Clinical Trials with Results: As of Dec, 2019
- Select Phase III Completed Clinical Trials with Results: As of December 30, 2019
- Breast Cancer
- Select FDA Approved Breast Cancer Drugs
- Breast Cancer Phase IV Completed Clinical Trials with Results: As of Dec 30, 2019
- Breast Cancer Select Phase III Completed Clinical Trials with Results: As of Dec 30, 2019
- Renal Cancer
- Select FDA-Approved Renal Cell Carcinoma Drugs
- Cervical Cancer
- Colorectal Cancer
- Select FDA-Approved Colorectal Cancer Drugs
- Skin Cancer
- Pancreatic Cancer
- Non-Hodgkin's Lymphoma
- Leukemia
- Standard Approved Mode of Therapy for AML by Age Group
- Blood Cancer Phase IV Completed Clinical Trials with Results: As of Dec 30, 2019
- Blood Cancer Phase III Completed Clinical Trials with Results: As of Dec 30, 2019
- Bladder Cancer
- Endometrial Cancer
FOCUS ON SELECT PLAYERS
- AbbVie, Inc. (USA)
- Amgen, Inc. (USA)
- Astellas Pharma, Inc. (Japan)
- AstraZeneca Plc. (UK)
- Bayer AG (Germany)
- Bristol-Myers Squibb Company (USA)
- Select Late Stage Compounds in Bristol-Myers Squibb Company's Oncology Pipeline (As of 2019)
- Celgene Corporation (USA)
- Eli Lilly and Company (USA)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Glaxosmithkline Plc (UK)
- Johnson & Johnson Services, Inc. (USA)
- Merck KGaA (Germany)
- Novartis AG (Switzerland)
- Pfizer, Inc. (USA)
- Takeda Pharmaceutical Company Limited (Japan)
For more information about this report visit https://www.researchandmarkets.com/r/opzov9
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
Share this article